Top 50 Biopharma Products 2011

Ronald A. Rader, president of the Biotechnology Information Institute provided Contract Pharma a list of the Top 57 Biopharma Products by 2011 revenues (in millions). Mr. Rader subscribes to the sam...

What is Enbrel?

Technical Background Tumor necrosis factor (TNF) is a substance made by your body's immune system. People with inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic a...

Abiraterone Acetate - Zytiga

On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...

Breast Implants - Augmentation

Breast implants are medical devices that are used to augment breast size or to reconstruct the breast following mastectomy or to correct a congenital abnormality. Breast implants consist of a silico...

What is Humira?

Technical background: HUMIRA is a tumor necrosis factor (TNF) blocker - further details can be viewed: Tumor Necrosis Factor TNF Cytokine Tumour Necrosis Factor (TNF) Mechanism of Acti...

How to feed data-hungry mobile devices? Use more antennas

(Rice University) Rice University researchers today unveiled Argos, a new multi-antenna technology that could help wireless providers keep pace with the voracious demands of data-hungry smartphones an...

Argos Therapeutics Expands Global Patent Protection

DURHAM, N.C., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the tre...

Argos Therapeutics Invited to Present at Two Biotech Industry Conferences

DURHAM, N.C., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the tr...

Argos Therapeutics Welcomes Jean Lamarre to Board of Directors

DURHAM, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the tr...

Argos Therapeutics to Present at the 12th Annual Needham Healthcare Conference

DURHAM, N.C., April 29, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the tr...

Argos Therapeutics to Present at the Stifel Nicolaus 2012 Healthcare Conference

DURHAM, N.C., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the tre...

Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial

DURHAM, N.C., July 2, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the trea...

Argos Therapeutics Validates Durability of AGS-003 Induced Immune Response in mRCC Patients

DURHAM, N.C., March 4, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the tre...

CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer.

BACKGROUND: Dendritic cells (DCs) are potent antigen-presenting cells that are central to the regulation, maturation, and maintenance of the cellular immune response against canc...

A comparison of decontamination effects of commercially available detergents in rats pre-exposed to topical sulphur mustard.

Objective: The genotoxic vesicant sulphur mustard [bis-2-(chloroethyl)sulphide] is a chemical warfare agent which is easily available due to its relatively simple synthesis. Thus, sulphur mustard is a...

Prevention of Chronic Renal Allograft Rejection by Soluble CD83.

BACKGROUND.: Recombinant human soluble CD83 had previously exhibited significant immunosuppressive properties that involved interference with dendritic cell maturation in both mouse and humans, inhibi...

Effect of CPAP treatment on endothelial function and plasma CRP levels in patients with sleep apnea.

Background: Continuous positive airway pressure (CPAP) is the most effective method for treating obstructive sleep apnea syndrome (OSAS) and alleviating symptoms. Improved sleep quality with effective...

Novel Influenza A (H1N1) infection vs. common Influenza-Like Illness: A prospective study.

Background: On June 11th, 2009 the World Health Organization (WHO) declared the first influenza pandemic of the 21st century. Data regarding the clinical characteristics and course of this viral infec...